Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 17/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25407252 | 1.00 | LTA4H (0.44) | LTA4HDRD2HTR2ADRD3MEN1 | |
| SCHEMBL25407150 | 0.91 | LTA4H (0.44) | LTA4H | |
| SCHEMBL25404417 | 0.87 | CYP11B1 (0.43) | LTA4HDRD2HTR2ADRD3 | |
| SCHEMBL25404424 | 0.87 | CYP11B1 (0.43) | LTA4HDRD2HTR2ADRD3 | |
| SCHEMBL23981032 | 0.85 | LTA4H (0.40) | LTA4H | |
| SCHEMBL23980870 | 0.85 | MEN1 (0.43) | MEN1KMT2A | |
| SCHEMBL27288015 | 0.85 | MEN1 (0.43) | MEN1KMT2A | |
| SCHEMBL25403420 | 0.85 | MEN1 (0.43) | MEN1KMT2A | |
| SCHEMBL23980911 | 0.80 | HTR3A (0.41) | LTA4H | |
| SCHEMBL26913648 | 0.80 | HTR3A (0.41) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | LTA4H 831/4885DRD2 2267/4885HTR2A 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.